Relay Therapeutics (RLAY) Accounts Payables (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Accounts Payables data on file, last reported at $4.1 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 51.43% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $4.1 million, a 51.43% decrease from a year earlier, with the FY2025 full-year figure at $7.7 million, down 45.34% from the prior year.
• Accounts Payables for Q1 2026 stood at $4.1 million, down from $7.7 million in the prior quarter.
• Over the last five years, Accounts Payables for RLAY reached as high as $14.8 million in Q2 2023 and fell as low as $2.8 million in Q3 2025.
• Historically, Accounts Payables has averaged $8.8 million across 5 years, with a median of $8.4 million in 2025.
• Across the five-year window, Accounts Payables soared 243.99% in 2023 and sank 59.92% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $10.6 million in 2022, then decreased by 12.92% to $9.2 million in 2023, then soared by 53.05% to $14.1 million in 2024, then plunged by 45.34% to $7.7 million in 2025, then slumped by 46.74% to $4.1 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $4.1 million in Q1 2026, $7.7 million in Q4 2025, and $2.8 million in Q3 2025.